CD8A and head and neck squamous cell carcinoma: Our earlier observations in vivo in HNSCC patients treated with pembrolizumab showed increases KCa3.1, but not Kv1.3, channels activity in CD8+ PBTs shortly after treatment (Newton et al., 2020).